Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × vandetanib × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 10 Thoracic 8 Gastrointestinal 7 Tumor-Agnostic 3 Sarcoma 2 Head & Neck 2 Endocrine 2 Breast 2 Other solid neoplasm 1 Other hematologic neoplasm 1 NET 1 Lymphoid 1 Genitourinary 1 Dermatologic 1

Conditions

Pheochromocytoma 1 Paraganglioma 1 Neuroendocrine Tumors 1

Interventions

Everolimus 10 lutetium Lu 177 dotatate 7 Magnetic Resonance Spectroscopy 7 pasireotide 4 Specimen Handling 3 Positron Emission Tomography Computed Tomography 3 Nivolumab 3 Ga(III)-DOTATOC 3 Fluorodeoxyglucose F18 3 (177)Lu-DOTA-EB-TATE 3 olaparib 2 gallium Ga 68 dotatate 2 amino-acid, glucose, and electrolyte solution 2 Temozolomide 2 Lutetium-177 2 Ipilimumab 2 FAPI-46 2 veliparib 1 vandetanib 1 trifluridine tipiracil drug combination 1 toripalimab 1 tislelizumab 1 talazoparib 1 surufatinib 1 romidepsin 1 peposertib 1 pembrolizumab 1 pelcitoclax 1 pegfilgrastim 1 lanreotide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01941849 2015-12-21

VIBRaNT

University College, London

Phase 1 Withdrawn

CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡